OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Lipidology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Editorial introductions	91
Familial hypercholesterolemia-Plus: is the metabolic syndrome changing the clinical picture of familial hypercholesterolemia?	89
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review	69
Genetic determinants of plasma lipids in Greenlanders	55
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease	44
Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism	39
Genetic variation in apolipoprotein A-V in hypertriglyceridemia	36
Polygenic risk scores in familial hypercholesterolemia. Do they have a role?	31
Alveolar macrophages: guardians of the alveolar lipid galaxy	27
The lipid-heart hypothesis from the Seven Countries Study of Cardiovascular Diseases	21
Implementation science and genetic testing for familial hypercholesterolemia	21
Oxidized LDL receptors: a recent update	20
Lipid metabolism during pregnancy: consequences for mother and child	20
Lipoprotein(a) and peripheral artery disease: contemporary evidence and therapeutic advances	20
Familial hypercholesterolemia in children and the importance of early treatment	20
Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19	20
Exosomes and lipid metabolism in metabolic and cardiovascular disorders	19
Universal screening for familial hypercholesterolaemia: how can we maximise benefits and minimise potential harm for children and their families?	19
Editorial introductions	19
Nutrition and its impact on cardiovascular disease	17
Nonalcoholic fatty liver disease: an update	17
Recent advances in understanding the spectrum of genetic determinants of lipoprotein(a) levels	16
Genetic determinants of pancreatitis risk in hypertriglyceridemia	15
A new SPRING in lipid metabolism	15
Familial hypercholesterolemia in pregnancy	15

From clinical development to real-world outcomes with inclisiran	14
Editorial introductions	14
The current state of apolipoprotein E in dyslipidemia	14
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?	13
The need for national and international registries of patients with elevated lipoprotein(a)	13
Genetic insights from Greenland: when geography, history and genomics converge	13
High-density lipoprotein functionality, cardiovascular health, and patterns of alcohol consumption: new insights and future perspectives	13
The complex pro-atherosclerotic role of lipoprotein(a): a multiplicity of cellular targets	13
Evolving guidelines on lipoprotein(a)	12
APOE and familial hypercholesterolemia	12
Can small dense LDL cholesterol be estimated from the lipid profile?	12
The intracellular chylomicron highway: novel insights into chylomicron biosynthesis, trafficking, and secretion	12
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?	12
Editorial introductions	11
Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent	11
The emerging role of fat-inducing transcript 2 in endoplasmic reticulum proteostasis and lipoprotein biogenesis	11
Cardiomyocytes, sphingolipids and cardio myotoxicity	10
Beyond cholesterol: linking the conformation of apolipoprotein B to atherogenesis	10
Newborn screening for lipid disorders	10
In the wake of the Scandinavian Simvastatin Survival Study trial	10
Distinct roles of size-defined HDL subpopulations in cardiovascular disease	9
Circulating protein and lipid markers of early sepsis diagnosis and prognosis: a scoping review	9
The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease	9
Pregnancy, cardiovascular health, and microchimerism	9
Altered cardiovascular risk pattern of LDL cholesterol in older adults	8
Genotype–phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia	8
Navigating variants of uncertain significance in genetic dyslipidemia: how to assess and counsel patients	8
Clinical associations between exercise and lipoproteins	8
Prevention of cardiometabolic diseases through dietary modifications	8
Editorial introductions	8
Strategies for management of patients with elevated lipoprotein(a)	8
Genetic testing for familial hypercholesterolemia	8
The pathophysiology of excess plasma-free cholesterol	8
The current landscape of prospective proteomics research into dementia using blood-based samples	7
Assessment of cardiovascular disease risk: a 2023 update	7
The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease	7
Beyond cellular distress: reframing GDF15 as a lipid-sensitive metabolic signal	7
Dietary fat, telomere length and cognitive function: unravelling the complex relations	7
A contemporary snapshot of familial hypercholesterolemia registries	7
Recent lipoprotein(a) trials	7
Lipidomics in gestational diabetes mellitus	7
HDL and ASCVD: is high HDL-C protective, harmful, or simply misleading?	7
How should low-density lipoprotein cholesterol be calculated in 2022?	6
Diagnosis of remnant hyperlipidaemia	6
Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations	6
Lipoprotein(a) in familial hypercholesterolemia	6
Atherogenic low-density lipoprotein and cardiovascular risk	6
Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events	6
Impact of mRNA and protein isoforms in lipoprotein metabolism and how to modulate them	6
Triglyceride-rich lipoprotein cholesterol and cardiovascular risk	6

Genetics of remnant cholesterol	6
Translating guidelines into practice via implementation science: an update in lipidology	6
Understanding the ins and outs of lipoprotein (a) metabolism	6
Predictors of cardiovascular risk in familial hypercholesterolemia	6
Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action	6
Resolution of apolipoprotein A1 and A2 proteoforms: their cardiometabolic correlates and implications for future research	6
Regulation of cardiovascular calcification by lipids and lipoproteins	5
Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism	5
Emerging regulators of endothelial lipid metabolism in atherosclerosis	5
Novel therapeutic opportunities for familial lecithin:cholesterol acyltransferase deficiency: promises and challenges	5
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees	5
Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density	5
Inflammation in atherosclerosis: a Big Idea that has underperformed so far	5
Are Lipoprotein(a) levels decreased in insulin resistance and type 2 diabetes?	5
Editorial introduction	5
Established and potential cardiovascular risk factors in metabolic syndrome: Effect of bariatric surgery	5
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity	4
Bempedoic acid: new evidence and recommendations on use	4
Inflammation and atherosclerotic cardiovascular disease: where do we go from here?	4
Editorial introductions	4
Cycling of metabolic states and metabolites as drivers of atherosclerosis	4
Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy	4
Lipoprotein (a) in familial hypercholesterolaemia	4
PCSK9-directed therapies: an update	4
Ultra-processed foods and CKD: a review of evidence, limitations, and future directions	4
Proprotein convertase subtilisin/kexin type 9 as a drug target for abdominal aortic aneurysm	4
G protein-coupled receptor 146: new insights from genetics and model systems	4
Circulating cell-free DNA and its association with cardiovascular disease: what we know and future perspectives	4
Editorial introduction	4
Macrophage cannibalism: efferocytosis in atherosclerosis	4
Editorial introductions	4